Machine signal
Active cluster sell — 9 distinct insiders, $78M, window ends Sep 29, 2026.
Figures computed from official regulatory filings — .
Analysttarget 257.47 USD (+24%) · consensus 4.7/5 · 22 buy · 1 hold · 0 sell
Ownershipinsiders 1.85% · institutions 100.98% · short 4.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Revolution Medicines, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
40 buys466 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Sandler Alan B. | Sell | $441.8K | SEC |
| Sandler Alan B. | Sell | $202.8K | SEC |
| Sandler Alan B. | Exercise | $353K | SEC |
| Sandler Alan B. | Sell | $244.5K | SEC |
| Sandler Alan B. | Sell | $324.6K | SEC |
| Sandler Alan B. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sandler Alan B. | Sell | $61.6K | SEC |
| Cislini Jeff | Sell | $158.6K | SEC |
| Mancini Anthony | Sell | $625.9K | SEC |
| Mancini Anthony | Exercise | $104.9K | SEC |
| Mancini Anthony | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mancini Anthony | Sell | $117.4K | SEC |
| ANDERSON ELIZABETH M | Sell | $959.8K | SEC |
| ANDERSON ELIZABETH M | Sell | $512.2K | SEC |
| ANDERSON ELIZABETH M | Exercise | $5.7K | SEC |
| ANDERSON ELIZABETH M | Sell | $19.5K | SEC |
| ANDERSON ELIZABETH M | Sell | $174.6K | SEC |
| ANDERSON ELIZABETH M | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ANDERSON ELIZABETH M | Sell | $291.9K | SEC |
| Mancini Anthony | Sell | $347.4K | SEC |
| Anders Jack | Sell | $11.9K | SEC |
| Kelsey Stephen Michael | Sell | $1.1M | SEC |
| Mancini Anthony | Sell | $5.3K | SEC |
| GOLDSMITH MARK A | Sell | $2.7M | SEC |
| Horn Margaret A | Sell | $14.8K | SEC |